Get the Stockscreener App
13.53
0.95%
-0.13
After Hours:
13.53
Relay Therapeutics Inc stock is traded at $13.53, with a volume of 5.36M.
It is down -0.95% in the last 24 hours and down -18.05% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$13.66
Open:
$13.52
24h Volume:
5.36M
Relative Volume:
1.58
Market Cap:
$2.59B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-8.3886
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
+10.90%
1M Performance:
-18.05%
6M Performance:
+99.85%
1Y Performance:
+375.57%
1-Day Range:
$13.40
$13.95
1-Week Range:
$11.62
$15.45
52-Week Range:
$2.75
$17.32
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
13.53 | 2.62B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume - MSN
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) - MSN
Relay rises on mid-stage trial data for lead asset in vascular anomalies - MSN
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN
Is Relay Therapeutics a Buy After Promising Trial Results? - Yahoo Finance
Relay Therapeutics prices $275M public offering of common stock at $12/share - MSN
Is Relay Therapeutics a Buy After Promising Trial Results? - The Motley Fool
New Forecasts: Here's What Analysts Think The Future Holds For Relay Therapeutics, Inc. (NASDAQ:RLAY) - Moomoo
Relay Therapeutics Announces $275 Million Public Offering of Common Stock – Details from SEC Form 8-K Filing - Minichart
Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release - Yahoo Finance
Relay Therapeutics Announces Major Underwritten Equity Offering - TipRanks
Relay Therapeutics Stock Rises on Promising Clinical Data and Analyst Upgrades - IndexBox
Relay Therapeutics Launches $12-Per-Share Equity Offering Under Jefferies, TD; Nets About $297 Million - TradingView
Relay Therapeutics (NASDAQ: RLAY) prices $296.8 million public stock offering - Stock Titan
Relay Therapeutics (RLAY) files $12 per-share offering for 22.9M shares - Stock Titan
RLAY Stock Surges As Zovegalisib Data Ignite Bullish Targets - StocksToTrade
Relay Therapeutics (RLAY) Launches $275M Public Offering at $12 Per Share - GuruFocus
Relay Therapeutics Prices $275 Million Public Offering - Moomoo
Relay Therapeutics: Encouraging Data, Competitive Risks (Downgrade) (RLAY) - Seeking Alpha
RLAY Technical Analysis | Trend, Signals & Chart Patterns | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
Relay Therapeutics prices $275M stock offering at $12/share By Investing.com - Investing.com Nigeria
Relay Therapeutics Announces Pricing of Public Offering of Common Stock - Investing News Network
Relay Therapeutics: Gross Expected to Be Approximately $275M >RLAY - Moomoo
RLAY Secures Larger Offering with Updated Terms - GuruFocus
Relay Therapeutics prices $275M stock offering at $12/share - Investing.com
Relay Therapeutics Prices Public Offering at $12 per Share - Intellectia AI
Relay Therapeutics announces pricing of public offering of common stock - marketscreener.com
Relay Therapeutics: Underwritten Public Offering of 22.9M Shares Priced at $12.00 Each >RLAY - Moomoo
Relay Therapeutics Announces Pricing Of Public Offering Of Common Stock - TradingView
Relay Therapeutics Shares Surge 8% Following Positive Analyst Ratings and Drug Results - Intellectia AI
Why Relay Therapeutics stock popped on Wednesday - MSN
Relay Therapeutics Shares Surge on Bullish Analyst Upgrades - Intellectia AI
Why Relay Therapeutics Stock Popped on Wednesday - The Globe and Mail
RLAY Maintained by Barclays -- Price Target Raised to $27.00 - GuruFocus
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):